Prolonged catatonic stupor successfully treated with aripiprazole in an adolescent male with schizophrenia: A case report

Clinical Schizophrenia and Related Psychoses

Volumn 4, Issue 3, 2010, Pages 185-188

  Kirino, Eiji ^a,b  

^a JUNTENDO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b JUNTENDO UNIVERSITY SHIZUOKA HOSPITAL   (Japan)

Author keywords

Adolescence; Aripiprazole; Catatonic stupor; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; RISPERIDONE;

ADOLESCENT; ARTICLE; CASE REPORT; CATATONIA; CLINICAL FEATURE; DISEASE DURATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; MALE; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; STUPOR; TREATMENT OUTCOME;

ADOLESCENT; ANTIPSYCHOTIC AGENTS; CATATONIA; HUMANS; JAPAN; MALE; PIPERAZINES; QUINOLONES; SCHIZOPHRENIA; STUPOR; TREATMENT OUTCOME;

EID: 77957678783     PISSN: 19351232     EISSN: None     Source Type: Journal    
DOI: 10.3371/CSRP.4.3.5     Document Type: Article

References (32)

1. Cohen D, Nicolas JD, Flament MF, Perisse D, Dubos PF, Bonnot O, et al. Clinical relevance of chronic catatonic schizophrenia in children and adolescents: evidence from a prospective naturalistic study. Schizophr Res 2005;76(2-3):301-308. (Pubitemid 40804776)
2. Thakur A, Jagadheesan K, Dutta S, Sinha VK. Incidence of catatonia in children and adolescents in a paediatric psychiatric clinic. Aust N Z J Psychiatry 2003;37(2):200-203. (Pubitemid 36592731)
3. Cohen D, Flament M, Dubos PF, Basquin M. Case series: catatonic syndrome in young people. J Am Acad Child Adolesc Psychiatry 1999;38(8):1040-1046. (Pubitemid 29353040)
4. Taylor MA, Abrams R. Catatonia. Prevalence and importance in the manic phase of manic-depressive illness. Arch Gen Psychiatry 1977;34(10):1223-1225.
5. Rosebush PI, Hildebrand AM, Furlong BG, Mazurek MF. Catatonic syndrome in a general psychiatric inpatient population: frequency, clinical presentation, and response to lorazepam. J Clin Psychiatry 1990;51(9):357-362.
6. Braunig P, Kruger S, Shugar G. Prevalence and clinical significance of catatonic symptoms in mania. Compr Psychiatry 1998;39(1):35-46. (Pubitemid 28051671)
7. Banerjee A, Sharma LN. Catatonia incidence in acute psychiatric admissions. Indian Journal of Psychiatry 1995;37(1):35-40.
8. Burris KD, Molski TF, Xu C, Ryan E, Tottori K, Kikuchi T, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302(1):381-389. (Pubitemid 34680462)
9. Tadori Y, Miwa T, Tottori K, Burris KD, Stark A, Mori T, et al. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur J Pharmacol 2005;515(1-3):10-19. (Pubitemid 40779262)
10. Kane JM, Carson WH, Saha AR, McQuade RD, Ingenito GG, Zimbroff DL, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry 2002;63(9):763-771.
11. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003;60(7):681-690. (Pubitemid 36818630)
12. Kasper S, Lerman MN, McQuade RD, Saha A, Carson WH, Ali M, et al. Efficacy and safety of aripiprazole vs. haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuropsychopharmacol 2003;6(4):325-337. (Pubitemid 38146250)
13. Kern RS, Green MF, Cornblatt BA, Owen JR, McQuade RD, Carson WH, et al. The neurocognitive effects of aripiprazole: an open-label comparison with olanzapine. Psychopharmacology (Berl) 2006;187(3):312-320. (Pubitemid 44079923)
14. Jordan S, Koprivica V, Chen R, Tottori K, Kikuchi T, Altar CA. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT1A receptor. Eur J Pharmacol 2002;441(3):137-140. (Pubitemid 34626163)
15. Hirose T, Uwahodo Y, Yamada S, Miwa T, Kikuchi T, Kitagawa H, et al. Mechanism of action of aripiprazole predicts clinical efficacy and a favourable sideeffect profile. J Psychopharmacol 2004;18(3):375-383. (Pubitemid 39382565)
16. Marder SR, McQuade RD, Stock E, Kaplita S, Marcus R, Safferman AZ, et al. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr Res 2003;61(2-3):123-136. (Pubitemid 36513927)
17. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia, second edition. Available from: URL: http://www.psychiatryonline.com/pracGuide/pracGuideTopic-6.aspx.
18. Fink M. Catatonia in DSM-IV. Biol Psychiatry 1994;36(7):431-433.
19. Philbrick KL, Rummans TA. Malignant catatonia. J Neuropsychiatry Clin Neurosci 1994;6(1):1-13.
20. Strawn JR, Delgado SV. Successful treatment of catatonia with aripiprazole in an adolescent with psychosis. J Child Adolesc Psychopharmacol 2007;17(5):733-735. (Pubitemid 350058979)
21. Kopala LC, Caudle C. Acute and longer-term effects of risperidone in a case of first-episode catatonic schizophrenia. J Psychopharmacol 1998;12(3):314-317. (Pubitemid 28548588)
22. Tan QR, Wang W, Wang HH, Zhang RG, Guo L, Zhang YH. Treatment of catatonic stupor with combination of modified electroconvulsive treatment and olanzapine: a case report. Clin Neuropharmacol 2006;29(3):154-156. (Pubitemid 44503894)
23. Van Den Eede F, Van Hecke J, Van Dalfsen A, Van den Bossche B, Cosyns P, Sabbe BG. The use of atypical antipsychotics in the treatment of catatonia. Eur Psychiatry 2005;20(5-6):422-429. (Pubitemid 41318009)
24. Northoff G. Catatonia and neuroleptic malignant syndrome: psychopathology and pathophysiology. J Neural Transm 2002;109(12):1453-1467. (Pubitemid 36061257)
25. Carroll BT. Kahlbaum's catatonia revisited. Psychiatry Clin Neurosci 2001;55(5):431-436.
26. Chung A, Varghese J. Treatment of catatonia with electroconvulsive therapy in an 11-year-old girl. Aust N Z J Psychiatry 2008;42(3):251-253. (Pubitemid 351234196)
27. Esmaili T, Malek A. Electroconvulsive therapy (ECT) in a six-year-old girl suffering from major depressive disorder with catatonic features. Eur Child Adolesc Psychiatry 2007;16(1):58-60. (Pubitemid 46648356)
28. Zaw FK. ECT and the youth: catatonia in context. Int Rev Neurobiol 2006;72:207-231.
29. Findling RL, Robb A, Nyilas M, Forbes RA, Jin N, Ivanova S, et al. A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry 2008;165(11):1432-1441.
30. Ainsworth P. A case of 'lethal catatonia' in a 14-year-old girl. Br J Psychiatry 1987;150:110-112.
31. Cornic F, Consoli A, Tanguy ML, Bonnot O, Perisse D, Tordjman S, et al. Association of adolescent catatonia with increased mortality and morbidity: evidence from a prospective follow-up study. Schizophr Res 2009;113(2-3):233- 240.
32. Kurahashi N. Attributes of aripiprazole, a third generation antipsychotic. BIOClinica 2007;22(8):719-725.